• images_6_.jpeg

    Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

    25 May, 2020
    Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.
    We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or...
  • arton15984.jpg

    Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

    22 May, 2020
    No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models.
    We did a randomised, d...
  • multi_drug.jpg

    Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

    21 May, 2020

    SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identif...
  • how_does_covid_kill.jpg

    Artificial intelligence–enabled rapid diagnosis of patients with COVID-19

    21 May, 2020

    For diagnosis of coronavirus disease 2019 (COVID-19), a SARS-CoV-2 virus-specific reverse transcriptase polymerase chain reaction (RT–PCR) test is routinely used. However, this test can take up to 2 d to complete, serial testing may be required to rule out the possibility of false negative results and there is currently a shortage of RT–PCR test kits, underscoring the urgent need for alternative methods for rapid and accurate diagnosis of patients with COVID-19. Chest computed tomography ...
  • antibodies.jpg

    Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward

    20 May, 2020

    Serological testing for SARS-CoV-2 has enormous potential to contribute to COVID-19 pandemic response efforts. However, the required performance characteristics of antibody tests will critically depend on the use case (individual-level vs. population-level).

    Click here for reference

  • images_5_.jpeg

    Prevalence of obesity among adult inpatients with COVID-19 in France

    19 May, 2020

    Most people who develop COVID-19 after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection present with paucisymptomatic and non-severe disease. However, approximately 20% of patients develop severe COVID-19 requiring hospitalisation, including 5% who are admitted to the intensive care unit (ICU). The ongoing COVID-19 outbreak has led to an unprecedented health crisis. Hence, it is crucial to identify individuals who are susceptible to developing severe COVID-19 and cou...
  • Captura_de_pantalla_2020-05-17_a_las_23_53_51.png

    Tracheostomy in the COVID-19 era: global and multidisciplinary guidance

    17 May, 2020
    Global health care is experiencing an unprecedented surge in the number of critically ill patients who require mechanical ventilation due to the COVID-19 pandemic. The requirement for relatively long periods of ventilation in those who survive means that many are considered for tracheostomy to free patients from ventilatory support and maximise scarce resources. COVID-19 provides unique challenges for tracheostomy care: health-care workers need to safely undertake tracheostomy procedures and ...
  • Captura_de_pantalla_2020-05-17_a_las_22_58_08.png

    Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans

    17 May, 2020
    The COVID‐19 pandemic has disrupted routine hospital services globally. This study estimated the total number of adult elective operations that would be cancelled worldwide during the 12 weeks of peak disruption due to COVID‐19.

    A global expert‐response study was conducted to elicit projections for the proportion of elective surgery that would be cancelled or postponed during the 12 weeks of peak disruption. A Bayesian beta‐regression model was used to estimate 12‐week cancellation rat...
  • 109484094_s-1-e1584525652779.jpg

    Reallocating Ventilators during the COVID-19 Pandemic: Is it Ethical?

    15 May, 2020
    The unprecedented COVID-19 pandemic has challenged our society to evaluate our core values and ethics. In a crisis like none other, health care facilities and physicians are now facing shortages of ventilators, beds, and even basic personal protective equipment. Many physicians are already facing a profound ethical dilemma: how to allocate these resources during shortages; with some hospitals, states and countries even having to establish policies on which groups of patients to prioritize in ...
  • 2000x1300_aidsmap.png

    COVID-19 in patients with HIV

    15 May, 2020

    We read with interest the report by Blanco and colleagues of five people living with HIV who were admitted to a Barcelona hospital with COVID-19. We believe that caution is required before drawing conclusions on the outcome of COVID-19 in this population. 

    Evidence is evolving that protease inhibitors developed for the treatment of HIV, both lopinavir and darunavir boosted by ritonavir or cobicistat, are not efficacious against severe acute respiratory syndrome cor...
  • descarga_19_.jpeg

    The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission

    15 May, 2020

    Speech droplets generated by asymptomatic carriers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are increasingly considered to be a likely mode of disease transmission. Highly sensitive laser light scattering observations have revealed that loud speech can emit thousands of oral fluid droplets per second. In a closed, stagnant air environment, they disappear from the window of view with time constants in the range of 8 to 14 min, which corresponds to droplet nuclei of&n...
  • merlin_171274968_51ac7536-702d-49ba-a674-4c29ebdf805f-superJumbo.jpg

    An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

    14 May, 2020
    The Bergamo province, which is extensively affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic, is a natural observatory of virus manifestations in the general population. In the past month we recorded an outbreak of Kawasaki disease; we aimed to evaluate incidence and features of patients with Kawasaki-like disease diagnosed during the SARS-CoV-2 epidemic.
    In the past month we found a 30-fold increased incidence of Kawasaki-like disease. Children diagnose...